SCHEMBL9909119

SCHEMBL9909119

CC(C)=NNC(=O)C(=O)NN=C(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
POLB P06746 1/20 0.44
CTH P32929 1/20 0.42
KDM4E B2RXH2 4/20 0.38
GAA P10253 3/20 0.38
HIF1A Q16665 1/20 0.38
RECQL P46063 1/20 0.36
CA1 P00915 2/20 0.35
AOC2 O75106 1/20 0.32
CA4 P22748 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CA2 P00918 1/20 0.32
PTGS1 P23219 1/20 0.32
MMP12 P39900 1/20 0.32
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
NFKB1 P19838 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131896 0.80
SCHEMBL1691078 0.78
SCHEMBL17119861 0.75
SCHEMBL20323218 0.75 CTH (0.44) MAPTCTHKDM4EGAARECQL
SCHEMBL24136136 0.75
SCHEMBL9909109 0.73 CTH (0.42) MAPTPOLBCTHKDM4EGAA
SCHEMBL204110 0.73
SCHEMBL15803698 0.73
SCHEMBL6055332 0.72
SCHEMBL2599790 0.71 CTH (0.36) MAPTCTHGAARECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790374-B2 Aqueous cross-linking compositions and methods COLUMBIA INSURANCE COMPANY (US) 2017-10-17 US disclosed
EP-2576708-B1 AQUEOUS CROSS-LINKING COMPOSITIONS AND METHODS MOORE BENJAMIN & CO (US) 2016-09-21 EP disclosed
US-9040617-B2 Aqueous cross-linking compositions and methods COLUMBIA INSURANCE COMPANY, INC. (US) 2015-05-26 US disclosed
US-20140228509-A1 Aqueous Cross-linking Compositions and Methods COLUMBIA INSURANCE COMPANY (US) 2014-08-14 US disclosed
WO-2013130248-A1 AQUEOUS CROSS-LINKING COMPOSITIONS AND METHODS BENJAMIN MOORE & CO. (US) 2013-09-06 WO disclosed
US-20120142847-A1 AQUEOUS CROSS-LINKING COMPOSITIONS AND METHODS COLUMBIA INSURANCE COMPANY (US) 2012-06-07 US disclosed
US-20100273924-A1 CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION SIKA TECHNOLOGY AG (CH) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273924-A1 CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION CA4, CTH, CA6 MAPT 399/4885POLB 1743/4885CTH 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.